Associated Papers
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Paternot S et al.
Molecular Oncology, 2024
CDK6 activity in a recurring convergent kinase network motif.
Gangemi CG et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2023
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X et al.
Nature Cancer, 2021
The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.
Müller A et al.
The Journal of Clinical Investigation, 2020
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.
Cornell L et al.
Cell Reports, 2019
CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X et al.
Plos Genetics, 2013
Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase.
Paternot S et al.
Cell Cycle (georgetown, Tex.), 2010
Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation.
Bockstaele L et al.
Molecular and Cellular Biology, 2009
Select a paper to view details